Oil-in-water method for making polymeric implants containing a hypotensive lipid
    1.
    发明授权
    Oil-in-water method for making polymeric implants containing a hypotensive lipid 有权
    用于制造含有低血压脂质的聚合物植入物的水包油法

    公开(公告)号:US08722097B2

    公开(公告)日:2014-05-13

    申请号:US11371118

    申请日:2006-03-08

    IPC分类号: A61K9/50 B01J13/02 B01J13/04

    摘要: Biocompatible microparticles include an ophthalmically active cyclic lipid component and a biodegradable polymer that is effective, when placed into the subconjunctival space, in facilitating release of the cyclic lipid component into the anterior and posterior segments of an eye for an extended period of time. The cyclic lipid component can be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the cyclic lipid component can be encapsulated by the polymeric component. The present microparticles include oil-in-water emulsified microparticles. The subconjunctivally administered microparticles can be used to treat or to reduce at least one symptom of an ocular condition, such as glaucoma or age related macular degeneration.

    摘要翻译: 生物相容的微粒包括眼科活性的环状脂质组分和可生物降解的聚合物,当放置在结膜下空间中时,有效地促进环状脂质成分延长眼睛部分的时间。 环状脂质组分可与可生物降解的聚合物基质相结合,例如两种可生物降解聚合物的基质。 或者,环状脂质组分可以被聚合物组分包封。 本发明的微粒包括水包油乳化微粒。 结膜下施用的微粒可用于治疗或减少眼部疾病如青光眼或年龄相关性黄斑变性的至少一种症状。

    Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems
    3.
    发明授权
    Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems 有权
    制备α-2激动剂聚合物药物递送系统的水包油法

    公开(公告)号:US07589057B2

    公开(公告)日:2009-09-15

    申请号:US11395019

    申请日:2006-03-31

    IPC分类号: A61K31/27 A61K31/535

    CPC分类号: A61K31/4166

    摘要: Biocompatible microparticles include an ophthalmically active alpha-2 adrenergic receptor agonist and a biodegradable polymer. The microparticles include oil-in-water emulsified microparticles which can be used to treat an ocular condition, such as glaucoma.

    摘要翻译: 生物相容性微粒包括眼科活性α-2肾上腺素能受体激动剂和可生物降解的聚合物。 微粒包括可用于治疗眼部疾病如青光眼的水包油乳化微粒。

    Memantine intravitreal implants
    5.
    发明申请
    Memantine intravitreal implants 审中-公开
    美金刚玻璃体内植入物

    公开(公告)号:US20050244473A1

    公开(公告)日:2005-11-03

    申请号:US11117879

    申请日:2005-04-29

    IPC分类号: A61K9/00 A61K31/13 A61F2/00

    CPC分类号: A61K9/0051

    摘要: Biocompatible intraocular implants include an anti-excitotoxic agent and a biodegradable polymer that is effective to facilitate release of the anti-excitotoxic agent into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma and proliferative vitreoretinopathy.

    摘要翻译: 生物相容性眼内植入物包括抗兴奋性毒性剂和可生物降解的聚合物,其有效促进抗兴奋性毒性剂长时间释放到眼睛中。 植入物的治疗剂可以与可生物降解的聚合物基质相关,例如基本上不含聚乙烯醇的基质。 植入物可以放置在眼睛中以治疗或减少一种或多种眼部病症的发生,例如视网膜损伤,包括青光眼和增生性玻璃体视网膜病变。

    Methods for treating ocular conditions with cyclic lipid containing microparticles
    6.
    发明申请
    Methods for treating ocular conditions with cyclic lipid containing microparticles 有权
    用含脂质的微粒治疗眼部病症的方法

    公开(公告)号:US20060246145A1

    公开(公告)日:2006-11-02

    申请号:US11371118

    申请日:2006-03-08

    摘要: Biocompatible microparticles include an ophthalmically active cyclic lipid component and a biodegradable polymer that is effective, when placed into the subconjunctival space, in facilitating release of the cyclic lipid component into the anterior and posterior segments of an eye for an extended period of time. The cyclic lipid component can be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the cyclic lipid component can be encapsulated by the polymeric component. The present microparticles include oil-in-water emulsified microparticles. The subconjunctivally administered microparticles can be used to treat or to reduce at least one symptom of an ocular condition, such as glaucoma or age related macular degeneration.

    摘要翻译: 生物相容的微粒包括眼科活性的环状脂质组分和可生物降解的聚合物,当放置在结膜下空间中时,有效地促进环状脂质成分延长眼睛部分的时间。 环状脂质组分可与可生物降解的聚合物基质相结合,例如两种可生物降解聚合物的基质。 或者,环状脂质组分可以被聚合物组分包封。 本发明的微粒包括水包油乳化微粒。 结膜下施用的微粒可用于治疗或减少眼部疾病如青光眼或年龄相关性黄斑变性的至少一种症状。

    Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
    7.
    发明申请
    Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods 审中-公开
    含有视网膜友好赋形剂的治疗眼用组合物及相关方法

    公开(公告)号:US20050250737A1

    公开(公告)日:2005-11-10

    申请号:US11091977

    申请日:2005-03-28

    摘要: Pharmaceutical compositions suitable for administration into the interior of an eye of a person or animal are described. The present compositions include one or more components which are effective in providing a reduced toxicity relative to existing intraocular ophthalmic compositions. The present compositions include one or more therapeutic agents in amounts effective in providing a desired therapeutic effect when placed in an eye, and one or more retinal friendly excipients that have a reduced toxicity relative to benzyl alcohol or polysorbate 80. In certain compositions, the excipient component of the compositions comprises one or more cyclodextrins or cyclodextrin derivatives. Methods of using the compositions to treat ocular conditions are also described.

    摘要翻译: 描述适于施用于人或动物的眼睛内部的药物组合物。 本发明组合物包括一种或多种有效提供相对于现有眼内眼用组合物的毒性降低的成分。 本发明的组合物包含一种或多种治疗剂,其用量在置于眼中时可提供所需的治疗效果,以及一种或多种视黄醛友好的赋形剂,其相对于苯甲醇或聚山梨酸酯80具有降低的毒性。在某些组合物中,赋形剂 组合物的组分包含一种或多种环糊精或环糊精衍生物。 还描述了使用组合物治疗眼睛病症的方法。

    Compositions and methods for localized therapy of the eye
    10.
    发明申请
    Compositions and methods for localized therapy of the eye 审中-公开
    眼睛局部治疗的组成和方法

    公开(公告)号:US20050181017A1

    公开(公告)日:2005-08-18

    申请号:US11039192

    申请日:2005-01-19

    摘要: Compositions, and methods of using such compositions, useful for injection into the posterior segments of human or animal eyes are provided. Such compositions include small particles of a poorly soluble therapeutic agent that facilitates formation of concentrated regions of the therapeutic agent in the retinal pigmented epithelium of an eye. The particles are formed by combining a therapeutic agent with an ophthalmically acceptable polymer component. The particles have sizes less than about 3000 nanometers, and in some cases, less than about 200 nanometers. One example of a composition includes particles of triamcinolone acetonide and hyaluronic acid have a size less than about 3000 nanometers.

    摘要翻译: 提供了组合物和使用这种组合物的方法,其可用于注射到人或动物眼睛的后段中。 这样的组合物包括促进在眼睛的视网膜色素上皮中形成治疗剂的浓缩区域的难溶性治疗剂的小颗粒。 通过将治疗剂与眼科可接受的聚合物组分组合来形成颗粒。 颗粒具有小于约3000纳米的尺寸,并且在一些情况下小于约200纳米。 组合物的一个实例包括曲安奈德的颗粒和透明质酸的尺寸小于约3000纳米。